ArticleMolecular therapy oncolytics2016

Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer.

Shingo Tsuji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.